Related Experiment Video

Updated: Jul 13, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Toll-like receptor 3 expressed by melanoma cells as a target for therapy?

Bruno Salaun1, Serge Lebecque, Sampsa Matikainen

  • 1Ludwig Institute for Cancer Research, Lausanne Branch, Epalinges, Switzerland.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|August 3, 2007
PubMed
Abstract

Insights

Toll-like receptor 3 (TLR3) agonists can directly kill melanoma cells and inhibit their growth. This dual action makes TLR3 agonists promising for cancer vaccines beyond their immune-boosting effects.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Toll-like receptors (TLR) agonists are explored as cancer vaccine adjuvants.
  • TLR expression extends beyond immune cells to tumor cells.
  • Investigating direct effects of TLRs on tumor cells is crucial.

Purpose of the Study:

  • To investigate Toll-like receptor 3 (TLR3) expression in melanoma.
  • To analyze the impact of TLR3 agonists on melanoma cell survival.
  • To determine TLR3's role in dsRNA-induced effects on melanoma viability.

Main Methods:

  • Assessed TLR3 protein expression in patient-derived melanoma cell lines.
  • Examined effects of TLR3 agonists on tumor cell survival.
  • Utilized RNA interference for stable TLR3 knockdown to study its involvement.

Main Results:

  • Human melanoma cells express functional TLR3 protein.
  • TLR3 activation by agonists inhibited proliferation and induced cell death (with IFN or protein synthesis inhibitors).
  • TLR3-mediated effects on cell death involve caspases and apoptotic pathways.

Conclusions:

  • TLR3 is expressed in human melanoma cells, mediating proapoptotic and antiproliferative signals.
  • TLR3 agonists offer dual benefits: immune stimulation and direct tumor cell effects.
  • TLR3 agonists show potential as cancer vaccine adjuvants due to cytostatic and cytotoxic properties.

More Related Videos

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...